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Abstract: (R,R) ZX-5 has been proven to have positive effects on choroidal blood flow 
without affecting the sclera and ciliary bodies in New Zealand white rabbits. This study 
was designed to investigate the mechanisms of (R,R) ZX-5 on improving the choroidal 
blood flow and promoting NO production. HUVECs (human umbilical vein endothelial 
cells) were used to determine the production of eNOS, p-eNOS, AKT and Erk1/2 by 
Western blot analysis. iNOS and eNOS mRNA levels were investigated by RT-PCR and 
the effect of (R,R) ZX-5 on NO production were determined by eNOS activity assay. We 
found (R,R) ZX-5 upregulated protein expression of eNOS and iNOS, increased NO 
production, and reduced ERK and Akt protein level. Therefore, (R,R) ZX-5 may promote 
the choroidal blood flow in New Zealand white rabbits without affecting the blood flow in 
the iris or ciliary bodies via increasing NO production. These results suggest that (R,R) 
ZX-5 may function to cure and prevent Age-related macular degeneration (AMD). 
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1. Introduction 
Age-related macular degeneration (AMD) is a progressive disease affecting nearly 50 million 
people worldwide [1,2]. It causes irreversible visual impairment and blindness which can be largely 
attributed to choroidal neovascularization (CNV), the development of abnormal blood vessels 
underneath the retina. Although CNV occurs only in 10% of AMD patients, it accounts for 90% of 
AMD-related blindness. The development of CNV has been linked to dysregulation of intercellular 
signaling molecules, such as nitric oxide (NO) [1–3], a key signaling messenger, which is synthesized 
in mammalian tissues by three distinct isoforms of NO synthase (NOS): neuronal NOS (nNOS), 
endothelial NOS (eNOS), and inducible NOS (iNOS). 
Insufficient NO production due to inadequate NOS activity can lead to various eye diseases, 
including AMD; consistent with this, increasing NOS activity can provide NO donors to the eyes, 
lower the intraocular pressure, increase ocular blood flow, and relax ciliary muscle [3]. 
We have designed and produced more than 200 NOS regulators, and one of them, (R, R)ZX-5, has 
been demonstrated to promote the blood flow of choroid but not sclera and cilliary bodies in New 
Zealand white rabbits [4]. (R,R) ZX-5 is the cis-form of 1-phenyl-3-{3-methoxy-2-propoxy-5- 
[4-(3,4,5-trimethoxy-phenyl)-1,3 -dithiolane-2-yl]-phenyl}-thiourea). Interestingly, the trans-form of 
the compound, (S,S) ZX-5, does not display any effects on the choroidal blood flow in New Zealand 
white rabbit [4], indicating that the choroidal blood flow promoting effect is (R,R) ZX-5 specific. 
However, molecular mechanism underlining the benefical effect of (R,R) ZX-5 has not been explained 
clearly. In this paper, we examined the role of (R,R) ZX-5 on the expression of eNOS and iNOS, and 
the possible signal molecules ERK and Akt, determinant of NO production.   
2. Materials and Methods 
2.1. The Structure of (R,R) ZX-5 
(R,R) ZX-5 was synthesized as described previously [4] and the structure is shown in Figure 1. 
Figure 1. The chemical structure of ZX-5. The cis form, (R,R) ZX-5, is shown on the left 
and the transform, (S,S) ZX-5, on the right. 
 
2.2. Cell Culture 
HUVECs (human umbilical vein endothelial cells) were obtained from Nanjing Keygen biotech Co. 
Ltd. (Nanjing, Jiangsu province, China) and maintained at 37 °C in an incubator with 5% CO2. 
HUVECs were cultured in basal medium Dubecco’s modified Eagle’s medium (DMEM) (Gibco, Int. J. Mol. Sci. 2010, 11                 
 
3325
Invitrogen Co., Carlsbad, CA, USA). The medium were supplement with 10% Fetal bovine serum 
(FBS) (Gibco, Invitrogen Co., Carlsbad, CA, USA) and 100 units/mL penicillin plus 50 μg/mL 
streptomycin. 
2.3. Measurement of NO Release  
Detection and quantification of NO produced by (R,R) ZX-5 treatment were conducted using the 
Griess assay method with the NO2/NO3 ASSAY KIT-C II (Dojindo Molecular Technologies, Inc., 
Rockville, MD, USA). Briefly, nitrite calibration curve and nitrate + nitrite calibration curves were 
first prepared, and the concentrations of nitrate and that of nitrate + nitrite in the sample were 
determined using the calibration curves. Finally, the nitrate concentration was calculated based on the 
equation:  
[Nitrate] = [Nitrate + Nitrite] – [Nitrite] 
2.4. Reverse-Transcriptase Polymerase Chain Reaction Analysis of eNOS and iNOS Expression 
Reverse transcriptase polymerase chain reaction (RT-PCR) was performed using the total RNA 
from HUVECs cells. The primers used were 5′-CCA GCT AGC CAA AGT CAC CAT-3′ (sense) and 
5′-AAA GCC TTC CGG AAG AGT CTC-3′ (antisense) for eNOS, 5′-CGT TTG ATG TCC GAG 
GCA-3′ (sense) and 5′-TGT GGT GAT GTC CAG GAA GTA-3′ (antisense) for iNOS, 5′-GTG AAG 
GTC GGA GTC AAC GGA TTT-3′ (sense) and 5′-CAC AGT CTT CTG GGT GGC AGT GAT-3′ 
(antisense) for GAPDH. The sizes of the RT-PCR products were 354 bp, 461 bp and 555 bp, 
respectively. Following electrophoresis, PCR products were analyzed using Labworks4 software 
(Gene Co. Ltd, HK). 
2.5. Western Blot Analysis 
For Western blot analysis, HUVECs were seeded at 3 × 10
5 per well in 6-well culture plates and 
incubated for 15 h with DMEM containing 10% FBS. The cells were then treated with (R,R) ZX-5   
(0, 7.5, 15 and 30 μg/mL) for 12 h. The cells were harvested with 0.05% trysin (Hyclone, UT, 
USA)/0.53 mM EDTA (Hyclone, UT, USA), washed in PBS, and resuspended in 100 μL of all 
Mammalian protein Extraction Reagent (Shanghai Generay Biotech Co. Ltd, Shanghai, China). The 
BCA protein assay kit (Bio-Rad, Hercules, CA, USA) was used to determine total protein 
concentration and purified bovine serum albumin (Sigma, NY, USA) to generate the standard curve. 
Concentrated protein were separated by 12% for ERK and AKT and 8% for eNOS, iNOS 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride 
(PVDF) membrane (Millipore, MA, USA). Briefly, PVDF membrane were incubated with a 1:1000 
dilution of MAP kinase1/2 (ERK), AKT, eNOS, iNOS, p-eNOS Ser
1177 and β-actin antibodies (Santa 
Cruz Biotechnology, CA, USA). After incubation with the appropriate secondary antibodies, blots 
were incubated with ECL reagents (Beyetime, Jiangsu province, China) and exposed to photographic 
film to detect protein expression. 
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2.6. Endothelial NO Synthase (eNOS) Activity Assay 
Endothelial cells were harvested in ice-cold buffer (20 mmol/L HEPES pH 7.4, 0.2 mol/L Sucrose, 
1 mmol/L EDTA, 1 mmol/L DTT, 2 mg/L Leupeptin, 2 mg/L aprotinin, 100 mg/L PMSF), and 
centrifuged to remove the cell debris. The supernatants were used for eNOS assay. The eNOS activity 
was determined as conversion of [3H] arginine to [3H] citrulline by incubating cell extracts for 10 min 
at 30 ºC in 10 μL (10 mM) NADPH, 0.5 μL l-[3H] arginine, 5 μL (16 mM) CaCl2, 1.2 μL (1 mM) 
arginine, and 3.3 μL ddH2O. Cell extracts incubated with the eNOS inhibitor, NG-nitro-l-arginine 
methylester (1 mm), served as the negative control. Converted citrulline was separated by unconverted 
arginine using the acidic ion exchange resin Dowex 50 W (200–400 mesh, 8% cross-linked, Sigma, St. 
Louis, MO, USA) as previously described [5]. Converted eNOS activity was obtained by counting per 
mg, per min value (cpm) of the [3H] citrulline. 
2.7. Statistical Analysis 
All values are expressed as the mean ± standard deviation (sd). Statistical differences between mean 
values were determined by one way ANOVA, followed by t test for comparison of mean values.   
P < 0.05 was considered statistically significance. 
3. Results  
3.1. (R,R) ZX-5 Treatment Increases NO Production in HUVECs 
In the rabbit, (R,R) ZX-5 treatment released a significant amount of NO at concentrations of 7.5, 15, 
and 30  μg/mL, and increased choroidal blood flow when 50 μL of 1% (R,R) ZX-5 solution was 
instilled into eyes. However, no such effect of the compound was observed in the blood flow of the iris 
or ciliary body [4]. The same results were observed in human endothelial cells. At 15 h following (R,R) 
ZX-5 treatment, NO production in HUVECs was increased in a dose-dependent manner (Figure 2). 
Figure 2. (R,R) ZX-5 enhances NO production in HUVECs: (R,R) ZX-5 significantly 
increasing NO production in a dose-dependent manner; (S,S) ZX-5 slightly increasing NO 
production in HUVECs. Data are presented as mean ± sd of 2 experiments. **P ≤ 0.01, 
compared with control cells. 
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3.2. (R,R) ZX-5 Up-Regulates iNOS mRNA in a Dose-Dependent Manner  
To test whether (R,R) ZX-5 increased NO production in response to iNOS and eNOS expression, 
we analyzed iNOS and eNOS mRNA levels in HUVEC cells in the presence or absence of (R,R) ZX-5 
using an RT-PCR assay. We found that (R,R) ZX-5 enhanced iNOS mRNA level in a 
concentration-dependent manner (Figure 3A, B) and had no effect on eNOS mRNA (Figure 3C, D) in 
HUVEC cells. Compared with DMSO stimulated control cells, cells treated with 30 µg/mL (R,R) 
ZX-5 for 15 hours displayed a significant upregulation of iNOS mRNA of approximately 258% 
(Figure 3B). 
Figure 3. Analysis of iNOS and eNOS mRNA levels in HUVECs after treatment with 0, 7.5, 
15, or 30 μg/mL(R,R) ZX-5 for 15 h. A and B: (R,R) ZX-5–induced iNOS transcription in 
HUVECs (of iNOS/GADPH). C and D: (R,R) ZX-5–induced eNOS transcription in 
HUVECs (of eNOS/GADPH). A and C are Western blots. In B and D, columns represent 
mean ± sd of experiments shown in A and C. *P ≤ 0.05 compared with control cells, n = 6. 
A                                     B  
 
 
C                                   D  
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3.3. (R,R) ZX-5 Treatment Leads to Increased iNOS and eNOS Protein Expression 
The iNOS and eNOS protein levels in (R,R) ZX-5-treated HUVEC cells were also analyzed and 
compared with those in DMSO stimulated cells. In DMSO-stimulated control cells, the production of 
eNOS protein was not affected. However, (R,R) ZX-5 treatment for 15 h induced a significant 
up-regulation of iNOS and eNOS protein (Figure 4 A and C), and (R,R) ZX-5 treatment for 3 h also 
induced a significant up-regulation of p-eNOS Ser
1177 protein (Figure 4E). HUVEC cells treated with 
30 µg/mL (R,R) ZX-5 exhibited a 80%, 62% and 71% increase in the iNOS, eNOS and p-eNOS 
Ser
1177 protein level (Figure 4B, D, and F), respectively. 
Figure 4. Western blot analysis of (R,R) ZX-5-induced iNOS and eNOS protein expression. 
A,  C,  E: protein expression of iNOS, eNOS and p-eNOS Ser
1177 in HUVECs; B,  D,  F: 
effects of (R,R) ZX-5 (0, 7.5, 15, 30 μg/mL for 15  hours)–induced iNOS, eNOS (of 
NOS/β-actin) and p-eNOS Ser
1177 ((of p-eNOS Ser
1177/total eNOS) protein expression in 
HUVECs. Columns represent mean ± sd of the experiments, *P ≤ 0.05 compared with 
control cells, n = 6. 
A                                   B  
       
 
C                                  D  
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Figure 4. Cont. 
E                                  F  
 
3.4. (R,R) ZX-5 Treatment Inhibits ERK and AKT Expression 
HUVEC cells were treated with various doses of (R,R) ZX-5 (0, 7.5, 15 and 30 μg/mL) for 15 h, 
followed by Western blot analysis of ERK and AKT from the cell lysates with anti-ERK and AKT 
monoclonal antibodies. As shown in Figure 5A and B, 30 μg/mL (R,R) ZX-5 treatment caused a 
significant decrease of ERK at the protein level (percentage decreases were 2.3%, 9.5% and 34.2% at 
7.5, 15 and 30 μg/mL (R,R) ZX-5, respectively). Notably, (R,R) ZX-5  reduced ERK1/2 protein 
expression in a dose-dependent manner. As shown in Figure 5C and D, (R,R) ZX-5 from 15 μg/mL 
treatment caused a significant decrease of AKT at the protein level (inhibition percentages were 1.2%, 
31.7% and 43.8% at 7.5, 15 and 30 μg/mL (R,R) ZX-5, respectively).   
Figure 5. Western blot analysis of ERK and Akt protein expression levels in HUVECs.  
(A,  C): Western blots showing protein expression of ERK and AKT in HUVECs, 
respectively; (B, D) the effect of (R,R) ZX-5 (0, 7.5, 15, 30 μg/mL for 15 h) on ERK and Akt 
protein expression in HUVECs, respectively, (of samples/β-actin). *P ≤ 0.05 compared with 
control cells, n = 6. 
A                                    B  
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Figure 5. Cont. 
C                                   D  
 
3.5. (R,R) ZX-5 Enhances eNOS Activity in HUVECs 
We further analyzed the total eNOS activity in HUVECs cells treated with DMSO, 7.5, 15, 
30 µg/mL (R,R) ZX-5 for 15 h. The eNOS activity assay was performed in the presence of [H
3] L-Cit. 
As seen in Figure 6, in (R,R) ZX-5 treated cells, the eNOS activity was significantly higher than that in 
the control. (R,R) ZX-5 enhanced eNOS activity in a concentration-dependent manner in HUVECs 
cells. Compared to the control, cells incubated with 30 µg/mL (R,R) ZX-5 for 15 h showed an increase 
in eNOS activity by 325%. 
Figure 6. The increased activity of eNOS after (R,R) ZX-5 treatment for 15 h. Columns 
represent mean ± sd of the experiment, *P ≤ 0.05, **P ≤ 0.01, compared with control cells,   
n = 6. 
 
4. Discussion 
Our prior study has shown that (R,R) ZX-5 promotes the release of NO and specifically increases 
choroidal blood flow in New Zealand white rabbit without affecting the blood flow in the iris or ciliary 
body [4], suggesting that (R,R) ZX-5 may be used for the prevention and treatment of AMD in   
elderly people.   Int. J. Mol. Sci. 2010, 11                 
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NO can be produced by three isoforms of NO synthase (NOS): endothelial NOS (eNOS), neural
 
NOS, and inducible NOS (iNOS). Although NO over-production by iNOS can be toxic, a low level of 
NO produced by constitutively
 expressed eNOS is necessary to maintain the normal endothelial 
function [6]. Thus, eNOS and iNOS appear to be attractive candidate genes of AMD susceptibility   
for analysis.   
Based on the structure, (R,R) ZX-5 is not a substrate of NOS. Thus, NOS cannot directly generate 
NO from (R,R) ZX-5. Instead, we show here that (R,R) ZX-5-enhanced NO production in HUVEC 
cells is via increased eNOS activity that results from up-regulation of eNOS expression at the protein 
level, also via increased iNOS expression at both the mRNA and protein levels. Activity of eNOS is 
known to be mainly regulated at the post-translational levels in a complex fashion by acylation, 
protein-protein interactions, intracellular trafficking, and phosphorylation. Signaling pathways that 
regulate eNOS activity include phosphoinositide 3-kinase/Akt, cyclic nucleotide-dependent kinases 
[PKA (protein kinase A) and PKG], PKC, as well as ERKs (extracellular-signal-regulated kinases) [7]. 
Mitogen-activated protein kinases (MAPKs) have been implicated in the regulation of NO 
production. However, the roles of ERK in eNOS regulation remain controversial. While inhibition of 
ERK signaling has been shown to attenuate eNOS activity stimulated by a variety of factors in several 
cell lines [8–12], it can also cause little change [13–16] or even an increase in eNOS activity [7,17]. 
Similarly, activated ERK phosphorylates eNOS in bovine aortic
 endothelial cells, leading to
 reduced
 
eNOS enzyme activity [18,19]. By contrast, our results showed that (R,R) ZX-5 simultaneously 
up-regulates eNOS protein activity and inhibiting ERK protein expression. The research indicates 
ERK might be involved in the regulation of eNOS activity by (R,R) ZX-5, further study needs to be 
done to identify the relationship between the expression and the activity of ERK and (R,R) 
ZX-5-induced eNOS activation. 
It is tempting to speculate that, upon (R,R) ZX-5 treatment, reduced ERK may lead to induced 
phosphorylation of eNOS, leading to enhanced eNOS activity and production of more NO in the cells. 
This proposed mechanism can be supported from the observation by Bernier et al. that ERK may 
directly phosphorylate eNOS in vitro, and that eNOS activity is enhanced by MEK/ERK inhibition in 
ATP-stimulated HUVECs [17]. Recently, enhanced eNOS activity in cells after MEK/ERK inhibition 
has also been reported by other researchers [7,19]. The present study proved that (R,R) ZX-5 affect 
eNOS protein expression and activity in an indirect manner by inhibiting ERK and thereby 
phosphorylating eNOS at alternative residues. 
Choroidal neovascularization (CNV) or choroidal angiogenesis is the creation of new blood vessels 
in the choroid layer of the eye; and this is a common symptom of the degenerative maculopathy wet 
AMD. It was found that the formation of CNV might have been inhibited or stopped by 
downregulation of the activity of the crucial key downstream effectors, Akt and ERK, of the PI3K/Akt 
and MEK/ERK pathway [20–23]. In our study, we found that (R,R) ZX-5 markedly downregulated the 
protein levels of Akt and ERK. These data suggest (R,R) ZX-5 may stop and inhibits the formation   
of CNV.   
In conclusion, the data presented here provide the first evidence that(R,R) ZX-5 has positive effects 
on NOS (eNOS and iNOS) and choroidal blood flow via the MEK/ERK- and PI3K/Akt -dependent 
signaling pathways. Therefore, our data will provide a potential role for （R,R） ZX-5 in the pathogenesis 
of diseases associated with AMD and will contribute to the development of new therapeutic strategies 
for AMD. Int. J. Mol. Sci. 2010, 11                 
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